Graft-versus-host disease screening

Jump to: navigation, search

Graft-versus-host disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Graft-versus-host disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Graft-versus-host disease screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Graft-versus-host disease screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Graft-versus-host disease screening

CDC on Graft-versus-host disease screening

Graft-versus-host disease screening in the news

Blogs on Graft-versus-host disease screening

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Graft-versus-host disease screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

Screening of the general population for GvHD is not recommended.

Screening

Screening of the general population for GvHD is not recommended. This is because GvHD can only occur in persons who undergo stem cell transplant, and only a very small fraction of persons will undergo stem cell transplant. The cost of screening to identify persons at risk would outweigh the benefits.

References



Linked-in.jpg